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ABSTRACT 

Purpose. The dermatopharmacokinetic methodology, in which tape stripping of the 
stratum corneum (SC) is used to access the amount of drug accumulated in the skin 
barrier, has been proposed for the quantification of topical drug bioavailability.  This 
investigation examined the clearance phase of a model drug from the SC after a short 
application of an infinite dose. 
Methods. A saturated solution of ibuprofen in propylene glycol/water was applied to the 
forearm of human volunteers for 30 minutes. The formulation was then removed and the 
drug profile across the SC was assessed immediately, and over the next 4 hours.  
Results. The clearance phase depends only on drug diffusivity in the SC.  However, the 
expected, progressive “flattening” of the concentration profiles with increasing time post-
formulation removal was not observed. It was subsequently deduced, using infrared 
spectroscopy, that the rapid percutaneous diffusion of propylene glycol, relative to 
ibuprofen, resulted in the transient maintenance of a saturated drug concentration at the 
SC surface even after removal of the original formulation.   
Conclusions. The important role of formulation excipients in topical delivery is 
demonstrated, and the local disposition of cosolvents within the SC may impact 
significantly on drug dermatopharmacokinetics and local bioavailability. 
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Introduction 
Optimization of topical drug bioavailability is an essential objective for the effective 
treatment of dermatological diseases. The assessment of the rate and the extent to which 
an active molecule attains its site of action on or within the skin, however, has not proved 
to be a facile task.  Nevertheless, because of pressure to facilitate the entry of generic 
products into the market, regulatory agencies, such as the U.S. Food and Drug 
Administration (FDA), have been exploring alternative approaches with which to 
characterise a drug’s dermatopharmacokinetics (DPK). One such method, involving the 
quantification of drug in the skin’s barrier layer, the stratum corneum (SC), as a function of 
time post-application and post-removal of the formulation, involves sampling of the 
“biophase” by repeated adhesive tape-stripping. Since the release, and the subsequent 
withdrawal, of a draft guidance from the FDA proposing a specific protocol (1), a number of 
detailed studies into the potential usefulness and limitations of the methodology have been 
published (2-19). 
The essence of a viable technique for evaluation of a drug’s DPK (and for the 
subsequent determination of bioequivalence between different products) involves 
assessment of classic metrics such as the maximum quantity of the active in the SC 
(Amax), the time at which that maximum level is reached (Tmax), and the area under the SC 
level versus time profile (AUC). Unlike the situation with oral drug administration, Amax, 
Tmax and AUC in the SC are not only dependent on the kinetics of absorption, they are also 
influenced importantly by the time at which drug administration is stopped by removal of 
any remaining formulation on the skin surface. Because percutaneous absorption is often 
a slow process, it is quite conceivable, and often the case, that the applied product will be 
removed (either deliberately or inadvertently) before the absorption phase is completed.  
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The majority of investigations undertaken to-date has focussed upon the absorption 
phase of DPK (2, 4, 8, 10, 11). These experiments have demonstrated the importance of 
quantifying the extent to which the SC is removed during tape-stripping, as well as 
providing evidence that the method can sensitively distinguish between formulations that 
are not equivalent (11). It has also been possible to interpret drug concentration profiles 
across the SC so as to deduce partitioning and diffusion parameters, which characterize 
the absorption process and which can subsequently be used to predict an entire 
absorption profile from a single short-contact duration experiment (10). 
Less attention, though, has been given to the elimination, or clearance, phase of the 
DPK profile, which, as articulated above, may have a significant impact on the key metrics 
classically derived from bioavailability and bioequivalence studies. Because topical 
formulations are typically complex, involving excipients which are volatile, or which can 
solubilize the drug within the outer SC but penetrate at different rates, or which act as 
enhancers that increase the permeability of the skin, there are manifold ways in which the 
constituents of a vehicle may influence DPK. The present study addresses, therefore, the 
clearance of a model drug, ibuprofen, subsequent to its application and removal in a DPK 
experiment. Ibuprofen, applied as a saturated solution in a 75:25 propylene glycol/water 
mixture, has been chosen for this work because a detailed examination of its absorption 
kinetics has already been undertaken and reported (9-11). Attention is focussed not only 
on the disposition of the active agent, but also on that of the common cosolvent employed, 
namely propylene glycol.  
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Materials and Methods 
1. Chemicals 
Racemic ibuprofen and propylene glycol were purchased from Sigma (Dorset, UK). 
Acetonitrile (HPLC grade) was obtained from Fisher Scientific (Loughborough, UK). All 
other chemicals were of analytical grade. 
2. Ibuprofen solubility and HPLC assay 
The solubility of ibuprofen at 20ºC in 75:25 (v/v) propylene glycol/water was 
determined as previously described (9) and was found to be 9.6 ± 0.7 mg/ml. 
The method was modified from that reported previously (9). The HPLC apparatus 
from Dionex (Surrey, UK) comprised: SOR-100 solvent rack, P680 pump, ASI-100 
automated sample injector, PD40 UV-Vis detector; Chromeleon software; C18 Acclaim 
120 column (4.6 x 250 mm; 5 µm). The eluent was a 55:45 mixture of acetonitrile and 0.1 
M citrate buffer at pH 2.4, pumped at a rate of 1.5 ml/min. Ibuprofen was detected at 223 
nm with a retention time of about 5 minutes. Linearity was obtained in the range of 0.5-20 
µg/ml; reproducibility, calculated as %RSD was 0.8%. No interfering peaks from either the 
tape adhesive or the SC were apparent. 
3. In vivo DPK experiments - Ibuprofen 
Five volunteers (3 female, 2 male, aged 24-60 years) with no history of 
dermatological disease participated in the study, which was approved by the local 
research ethics committee (Royal United Hospital, Bath, UK). Informed consent was 
obtained from each subject.  The procedures followed have been reported in the literature 
(2) and involved two distinct components. 
In a first set of experiments, SC thickness for each volunteer was determined at a 
site on the ventral forearm adjacent to those used subsequently for the DPK 
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measurement. A circular template (diameter: 2 cm) delimited a specific skin area at which 
a baseline measurement of transepidermal water loss (TEWL) was made in triplicate 
(Aquaflux, Biox Systems Ltd, London, UK) and averaged. Pre-weighed adhesive tapes 
(2.5 X 2.5 cm, Scotch Booktape #845, 3M Co., St Paul, MN) were then sequentially 
applied over the template-delimited area, rubbed back and forth six times with stainless 
steel tweezers, and then removed to collect progressively layers of the SC. Between each 
strip, TEWL was measured as before. Stripping continued until the value of TEWL had 
reached 4 times the baseline or 60-70 g/m2/h, which corresponds to the removal of at least 
75% of the total SC thickness (20) Each tape was reweighed to determine the mass of SC 
removed. Then, knowing the area of the SC stripped, and assuming a SC density equal to 
1 g/cm3 (21), the thickness of the SC removed on each strip and the cumulative thickness 
removed, were calculated. Finally, following a published procedure (20), values of 1/TEWL 
were plotted against the cumulative SC thickness removed (µm), yielding a straight line, 
the x-axis intercept of which equalled the SC thickness. This exercise permitted all 
subsequent DPK data to be normalized for each subject and presented as concentration 
profiles as a function of relative SC depth (from 0 at the surface to a value of 1 at the inner 
boundary of the SC). 
Secondly, ibuprofen DPK measurements were then conducted on the ventral 
forearms of the same volunteers. Drug application involved a saturated solution (~10 
mg/ml) in 75:25 (v/v) propylene glycol/water. The solution applied (500 µl) was constrained 
by a plastic template (diameter: 2.5 cm) to prevent spreading and spillage, and was 
covered with an occlusive bandage during the 30-minute administration period. At the end 
of the treatment, excess solution was removed, and the SC surface was blotted completely 
dry with absorbent tissue. The site was then either stripped immediately or left unoccluded 
for 30 minutes or 1,2,3 or 4 hours before stripping. In one further set of experiments, a 
delay time of 30 minutes was again employed but the treated site was occluded during this 
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period (Figure 1). The tape-stripping and TEWL measurement procedures described 
previously (for the SC thickness determination) were again adopted here, but with less 
frequent determinations of TEWL to allow the strips to be collected as quickly as possible. 
Once tape-stripping had concluded, the tapes were reweighed and then placed 
individually in glass vials containing 1 ml of a 75:25 (v/v) mixture of acetonitrile and water 
into which ibuprofen was extracted over the next 4 hours (8). Recoveries were >99%. 
Finally, the extracts were assayed by HPLC for ibuprofen using the method described 
above. Results were then expressed as ibuprofen concentration profiles in the SC (µmol of 
drug per mg of SC) as a function of the relative depth into the barrier (x/L where x is the 
cumulative depth and L the absolute thickness of the SC in µm) 
4. In vivo DPK experiments - Propylene glycol 
A separate set of experiments was undertaken in the same volunteers to track the 
disposition of the cosolvent, propylene glycol. In this case, detection of the chemical 
utilized attenuated total reflectance, Fourier-transform infrared spectroscopy (ATR-FTIR) 
(22). The spectrophotometer (Nicolet 520P, Madison, WI) was equipped with a mercury– 
cadmium–telluride detector and a ZnSe reflectance element (45°, 7x1x0.2 cm, Spectra-
Tech, Inc., Shelton, CT). Spectra (32 scans, 4 cm-1 resolution) were collected over the 
range of 4000 to 400 cm-1, with particular attention focussed on the C-O stretching 
vibration from propylene glycol at 1040 cm-1. 
A large template (8x2 cm2) was used to provide a treated skin area comparable to 
that of the ATR reflectance element. Application of a 75:25 (v/v) mixture of propylene 
glycol and water lasted 30 minutes, at the end of which excess liquid was removed and 
the skin surface completely cleaned as before. The deposition of propylene glycol in the 
SC was then evaluated immediately or after a 30-minute delay, during which time the 
treated area was either kept under occlusion or left open to ambient conditions. The fate of 
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the cosolvent was monitored in two different ways: either at skin surface at a function of 
time, or within the SC via the use of tape-stripping. 
In the former case, post cleaning of the skin, the volunteer’s arm was positioned 
and remained on the ATR reflectance element for the next 30 minutes. Spectra were 
recorded every 5 minutes, which was considered a reasonable period with respect to the 
time necessary for the spectrum to be recorded (~0.5 minutes) and sufficient to allow for a 
measurable amount of co-solvent transport to have occurred; in this first instance, 
therefore, the application site was effectively occluded during the data collection period. A 
subsequent experiment was then performed in which the arm was removed from the 
reflectance element between each spectrum acquisition; in other words, under non-
occluded conditions. Because the degree of skin contact with the ZnSe crystal is not 
reproducible, data from these measurements are presented as the semi-quantitative ratio 
of the area under the C-O absorbance peak at 1040 cm-1 from propylene glycol to that 
under the amide I and amide II bands (originating from carbonyl stretching and N-H 
bending vibrations from SC keratin) (23-26) (Figure 2).  
In the latter case, the propylene glycol profiles across the SC were determined. 
First, after the 30-minute treatment and post-cleaning, the skin was immediately tape-
stripped. Each strip was rapidly transferred to the ZnSe crystal for an IR spectrum to be 
recorded. While this was being carried out, the next tape had been applied and was able 
thereby to keep the treated site occluded. Due to the volatility of propylene glycol, and the 
risk that the cosolvent might be inadvertently “lost” (27), all transfers were performed as 
quickly as possible and the tapes, in this series of experiments, were not weighed before 
and after stripping as they has been in the ibuprofen component of the work. The 
procedure, as outlined, was then conducted on two further occasions after a 30-minute 
delay post-application of the vehicle and following surface cleaning. In one instance, the 
treated site was occluded during the delay; in the other, it was not. 
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For these experiments, in which propylene glycol absorbance on the tapes as a 
function of the depth into the SC was determined, it was possible to develop a calibration 
curve so that the results could be expressed quantitatively in terms of the amount of 
cosolvent per cm2 of SC. This was achieved with a method previously reported (28) 
wherein tape-strips, on which removed SC was present, were “doped” with different 
amounts of propylene glycol and then subsequently read by ATR-FTIR. The calibration 
curve covered the range of 7 to 70 µg/cm2 over which linearity was excellent. Above 13 
µg/cm2, the percentage relative error and the relative standard deviation were below 20%. 
Table I summarises the details of this analytical validation.  
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Results and Discussion 
The first DPK experiment involved determination of the ibuprofen concentration 
profile across the SC immediately following a 30-minute application of the drug as a 
saturated solution in 75:25 (v/v) propylene glycol/water. The results from the five 
volunteers are in Figure 3 and are presented as a function of relative depth into the barrier, 
a normalization procedure made possible by the independent assessment of individual SC 
thicknesses as described above. Despite the relatively small number of subjects involved 
in this study, the data were reasonably reproducible and in line with recently published 
work (10). As before, the profiles were fitted to the applicable solution to Fick’s second law 
of diffusion (7), assuming that drug diffusivity in the SC is slow compared to uptake by the 
cutaneous microcirculation, and that “sink” conditions apply for the drug at the SC-viable 
epidermis interface: 
⎡ 2 2 2 ⎤ x 2 ∞ exp ⎣⎡−m π tapp (D L  )⎤ sin (mπ x L  )⎦Cx = K  C  v ⎢1− − ∑ ⎥    Eq.  1  ⎢ L π m=1 m ⎥ ⎣ ⎦ 
where Cx is the drug concentration at position x in the SC at time tapp and Cv is the drug 
concentration in the vehicle. The fitting yields values for the drug’s SC-vehicle partition 
coefficient (K) and for D/L2, a first order rate constant comprising the ratio of the drug 
diffusivity (D) in the SC to the thickness (L) squared of the barrier (2). The derived results 
for K and D/L2 are also given in Figure 3; the means (± SD) were 2.99 (±0.66) and 0.21 
(±0.04) h-1, respectively, and were not significantly different from those reported previously 
(7). The integrated amounts in the SC were derived from the areas under the profiles in 
Figure 3 and yielded a mean (± SD) value of 12.2 (±3.5) µg/cm2. The coefficient of 
variation of the DPK parameters obtained was around 20% supporting the robust nature of 
this in vivo experiment and the analysis of the resulting data. 
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The next phase of investigation was to evaluate the clearance of drug from the SC 
as a function of time post-removal of the applied formulation. While uptake in the SC is 
controlled by partitioning and diffusion, clearance is dominated by diffusion alone.  In this 
case, assuming that the drug is non-volatile (i.e., that it is not lost from the SC to the air by 
evaporation), the concentration profile during the clearance phase is described by Eq. 2 
(29) (see Appendix): 
2 2 2∞ ⎪⎧⎡ ∞ exp ⎣⎡−m π tapp (D / L )⎦⎤ ⎤ 2 2 ⎪⎫1Cx = 2K  C  v ∑⎨⎢ 2 − 2∑ 2 2 2 ⎥ cos  (λnx / L) exp  ⎡−λn (t − tapp  ) (D / L )⎤⎬ Eq. 2⎣ ⎦ 
n=0 ⎪⎢λn m=1 m π − λn ⎥ ⎪⎩⎣ ⎦ ⎭ 
where Cx is again the drug concentration at position x in the SC, tapp is the time for which 
the formulation was applied and λn= (2n+1)π/2. Using the average values of K and D/L2 
from the initial DPK measurements and setting (t - tapp) equal to 0.5, 1, 2, 3 and 4 hours 
following an application time of 30 minutes, Equation 2 was used to generate predicted 
ibuprofen concentration profiles across the SC during the clearance phase. These results 
are compared with the experimental data subsequently obtained in Figure 4.  The absence 
of agreement between theory and experiment is clear. The anticipated decay and 
flattening of the concentration profile is not observed; in fact, the total amount of ibuprofen 
(in µg/cm2) within the SC hardly changed at all during the 4 hours clearance period (Table 
II).  
The DPK literature on ibuprofen delivery into the SC reveals that uptake from 
saturated solutions containing different percentages of propylene glycol was far from 
constant, with significantly more drug being made available as the presence of the 
cosolvent increased (9). The simplest explanation for these findings is that propylene 
glycol itself entered in the SC in significant amount and thereby enabled the solubility of 
the drug in the membrane to be increased. Once this has been achieved and the driving 
force for diffusion removed (i.e., upon removal of the formulation to initiate the clearance 
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phase), the elimination of both drug and cosolvent from the SC will proceed. However, if 
propylene glycol clearance is faster than that of ibuprofen (a possible scenario given the 
difference in their molecular weights and recognising that propylene glycol is somewhat 
volatile), the enhanced solubility of the drug in the SC will not be sustained, it will 
precipitate within the SC and, hence, be unable to diffuse out of the membrane. 
Subsequent experiments examined this hypothesis. 
First, the ibuprofen profile across the SC was measured once again after a 30­
minute delay between the 30-minute application and the tape-stripping procedure. 
However, in this case, the treated site was occluded during the delay period, rather than 
being left open to ambient conditions as before (Figure 4). The impact of this modification 
is apparent in Figure 5, which shows that, when propylene glycol was prevented from 
evaporative loss at the SC surface, ibuprofen remained able to diffuse from the SC. While 
the concentration profile does not overlay perfectly the predicted behaviour from Eq. 2, the 
change relative to the unoccluded experiments is definitely in the right direction.  
Second, rather than infer the behaviour of propylene glycol at the skin surface, 
ATR-FTIR was performed to track the presence of the cosolvent following termination of 
the 30-minute application period. The characteristic absorbance from propylene glycol C-O 
stretching was used to assess the disappearance of the compound over a period of one 
hour from the outermost layer of the SC, either when the site was occluded or unoccluded. 
Figure 6 demonstrates that the cosolvent was lost by both evaporation and diffusion into 
and through the SC (as has been previously observed in a detailed investigation of 
minoxidil delivery from vehicles which also contained ethanol (27)), in that more propylene 
glycol disappeared from the surface when it was not protected between IR measurements. 
Roughly speaking, over the 1-hour measurement period, about 30% of the initial signal 
was lost when the site was occluded, compared to nearly 60% when it was not, suggesting 
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that evaporative and diffusive clearance mechanisms contributed about equally to the 
results obtained. 
Third, a further DPK study was undertaken to evaluate the concentration profile of 
propylene glycol itself across the SC under different experimental conditions. Skin was 
treated with 75:25 (v/v) propylene glycol/water for 30 minutes, cleaned and then either (i) 
stripped immediately, or (ii) either occluded for a further 30 minutes, or left open to 
ambient conditions for 30 minutes, and then stripped. Propylene glycol in the tape-strips 
was quantified by ATR-FTIR using a previously validated calibration procedure described 
in the Materials & Methods. Immediately post-application there was a steep concentration 
gradient of the cosolvent across the SC (Figure 7). The area under the profile provides the 
cumulative amount of propylene glycol in the SC at this time: 150 ± 27 µg/cm2, a value in 
good agreement with a report in the literature describing the quantification of the 
compound by GC-MS in human skin following a 30-minute application of the pure material 
(110 ± 40 µg/cm2) (30). When the treated skin was tape-stripped after a 30-minute delay, 
during which time the treated area was kept under occlusion, the propylene glycol 
concentration profile decreased (Figure 7) and the amount recovered from the SC fell to 
59 (±16) µg/cm2. Repeating the experiment with the treated site unoccluded during the 30­
minute delay both reduced the amount of cosolvent recovered (84 (±10) µg/cm2) and 
altered the shape of the profile (Figure 7). Notably, there was significantly less propylene 
glycol in the surface SC layers, presumably because the compound had now been lost 
from the barrier both by diffusion through the membrane and by evaporation to the 
atmosphere (although which of these two loss processes dominates is difficult to deduce 
(27)). 
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Conclusions 
In summary, the results reported in this paper confirm that the disposition and fate 
of a topically applied drug are not only dependent upon its physicochemical properties 
(size, lipophilicity, etc.), but also upon the manner in which the active species is presented 
to the skin; that is, the formulation. Even with the simple cosolvent vehicle employed here, 
the behaviour of one constituent (propylene glycol) is also complex and has a direct 
influence on the drug’s dermatopharmacokinetics, not only during the uptake phase, as 
has already been examined in depth in other work, but also during the clearance of the 
active from the SC. It follows that comparison between putatively bioequivalent topical 
drug products must involve careful examination of the potential effects of different 
excipients and the manner in which their behaviour may impact on the rate and extent at 
which the active attains its site of action. It should also be emphasised that the behaviour 
observed in this research may be even more pronounced when the amount of co-solvent 
applied is similar to that typically used in clinically-approved products (as opposed to the 
higher levels which have been used here). 
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Appendix 
The concentration of drug in the stratum corneum (SC) during clearance is 
described by Fick’s second law: 
∂C ∂2C = D 2          Eq.  A1  ∂t ∂x 
where the concentration at time tapp is defined by Eq. 1, the flux of drug from the surface of 
the stratum corneum is zero, and sink conditions apply at the interface between the SC 
and viable epidermis: 
∂C = 0 at x = 0 ∂x 
C = 0 at x = L 
Eq. A1 is solved for these boundary conditions by separation of variables to obtain Eq. 2 
(19). 
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Table I: Details of the analytical method used to quantify propylene glycol on tape-
strips of SC. The linear calibration curve was y = 4.87 + 0.69x; r2= 0.93 
Nominal amount of 
propylene glycol (µg/cm2) 
Fitted value 
(µg/cm2) n RSD% ER % 
6.9 11.1 7 21.7 60.1 
13.8 12.2 7 16.95 13.6 
27.6 23.2 7 19.22 16.79 
35.7 38.8 5 17.79 17.65 
57.1 56.1 5 6.30 4.88 
71.4 81.9 1 - 14.7 
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Table II: 	 Quantity of ibuprofen (mean ± SD, n=5) in the SC following a 30-minute 
application of a saturated drug solution in 75:25 (v/v) propylene 
glycol/water under different clearance conditions as specified in the text. 
Delay (h) Ibuprofen (µg/cm2) 
0	 13.6 ± 4.1 
0.5	 17.4 ± 0.9 
1	 10.2 ± 1.8 
2	 9.3 ± 1.4 
3	 10.5 ± 4.6 
4	 9.7 ± 2.9 
0.5 (occluded)	 7.3 ± 1.0a 
aValue statistically different from those when the delay was either 0 or 0.5 h (p<0.05). The significance of any 
differences between values was assessed using ANOVA followed by the Bonferroni test. 
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Figure legends 
Figure 1. Schematic representation of the DPK experiments performed to assess the 
clearance of ibuprofen from the SC following its topical application to the 
skin. 
Figure 2. Typical ATR-FTIR spectrum from human skin in vivo after a 30-minute 
contact with a 75:25 (v/v) mixture of propylene glycol and water. The C-O 
stretching absorbance band from the cosolvent and the amide I and amide II 
absorbance from SC keratin are highlighted. 
Figure 3. Ibuprofen concentration profiles across the SC of 5 volunteers immediately 
following a 30-minute application of a saturated drug solution in 75:25 (v/v) 
propylene glycol/water. The best fits of Eq. 1 to the data are represented by 
the solid lines, and the derived value (mean ± SD) of the drug’s SC/vehicle 
partition coefficient (K) and diffusivity parameter (D/L2), as well as the total 
uptake of drug into the SC (AUC) are shown in the table insert.  
Figure 4. (A) Theoretically predicted concentration profiles of ibuprofen across the SC 
following a 30-minute treatment, followed by various periods of delay during 
which the drug is expected to clear from the skin. The profiles were 
determined using Eq. 2 and the average values of K and D/L2 derived from 
the data in Figure 3. (B) Example of experimentally determined results 
following the protocol outlined in Figure 1(a). 
Figure 5. Typical ibuprofen concentration profiles across the SC following a 30-minute 
application of a saturated solution in 75:25 (v/v) propylene glycol/water and 
then either (i) tape-stripping Immediately (filled circles), or (ii) tape-stripped 
after a further 30-minutes during which time the skin was either occluded 
(filled squares) or open to ambient conditions (open circles). The dotted line 
represents theoretical “delay = 0” curve calculated using Eq.1; the solid line 
represents the theoretical “delay = 30 minutes” curve calculated using Eq.2.  
Figure 6: Relative levels (determined by ATR-FTIR) of propylene glycol remaining in 
the SC as a function of time after a 30-minute application of a 75:25 (v/v) 
mixture of cosolvent and water. Post treatment and cleaning of the skin 
surface, the site was either maintained under occlusion (closed symbols) or 
left open to the ambient condition in between the acquisition of spectra (open 
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symbols). The data have been corrected by the background signal at 1040 
cm-1 observed when the SC has not been exposed to propylene glycol.  
Figure 7:	 Propylene glycol concentration profiles (mean ± SD; n=5) across the SC 
(expressed in terms of tape strip number) following a 30-minute application of 
a 75:25 (v/v) mixture of cosolvent and water and then either (i) tape-stripping 
immediately (filled circles), or (ii) tape stripped after a further 30 minutes 
during which time the skin was either occluded (filled squares) or open to 
ambient conditions (open circles). 
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